LivaNova PLC Overview
Pro stress-test →LivaNova advances patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies. The company delivered double-digit revenue growth in 2025 with full-year revenue of $1.39 billion, increasing 10.7% on an organic basis. With operations in over 100 countries and strategic expansion into emerging markets like obstructive sleep apnea, the company is positioned as a market leader in critical care and neuromodulation.
Strategic Profile
Pro stress-test →LivaNova is pursuing strategic growth in high-growth segments such as obstructive sleep apnea and digital health for neuromodulation, while maintaining durable market share and profit gains in core Cardiopulmonary and Epilepsy businesses. The company is investing in advanced R&D, digital capabilities with FDA-approved platforms, and scaling next-generation manufacturing while deleveraging its balance sheet.
Competitive Landscape
Pro stress-test →Increased competition risks are noted in the field, with valuation compression expected as growth moderates. Main competitive risks include supply chain constraints and slow penetration rates in new markets. LivaNova competes in cardiac surgery devices and neuromodulation therapy against larger diversified medical device companies.
Industry Context
LivaNova PLC operates in Medical Devices - Cardiac Surgery & Neuromodulation.
Key facts
Founded: 2015 · Headquarters: London, United Kingdom · Employees: 3,300 · Revenue: $1.39B · Market cap: $3.84B